S&P 500   5,080.33 (+0.21%)
DOW   38,931.26 (-0.05%)
QQQ   438.28 (+0.69%)
AAPL   181.05 (-0.20%)
MSFT   407.62 (-0.02%)
META   488.94 (+1.02%)
GOOGL   136.96 (+0.43%)
AMZN   174.60 (+0.83%)
TSLA   200.76 (-0.63%)
NVDA   792.88 (+2.09%)
NIO   5.66 (+4.24%)
AMD   187.02 (+5.94%)
BABA   74.17 (-0.56%)
T   17.00 (+0.24%)
F   12.43 (+1.06%)
MU   89.56 (-0.17%)
CGC   3.33 (-0.89%)
GE   155.99 (+0.24%)
DIS   111.46 (+0.60%)
AMC   4.38 (-12.22%)
PFE   26.97 (-0.26%)
PYPL   60.79 (+0.90%)
XOM   104.42 (+0.10%)
S&P 500   5,080.33 (+0.21%)
DOW   38,931.26 (-0.05%)
QQQ   438.28 (+0.69%)
AAPL   181.05 (-0.20%)
MSFT   407.62 (-0.02%)
META   488.94 (+1.02%)
GOOGL   136.96 (+0.43%)
AMZN   174.60 (+0.83%)
TSLA   200.76 (-0.63%)
NVDA   792.88 (+2.09%)
NIO   5.66 (+4.24%)
AMD   187.02 (+5.94%)
BABA   74.17 (-0.56%)
T   17.00 (+0.24%)
F   12.43 (+1.06%)
MU   89.56 (-0.17%)
CGC   3.33 (-0.89%)
GE   155.99 (+0.24%)
DIS   111.46 (+0.60%)
AMC   4.38 (-12.22%)
PFE   26.97 (-0.26%)
PYPL   60.79 (+0.90%)
XOM   104.42 (+0.10%)
S&P 500   5,080.33 (+0.21%)
DOW   38,931.26 (-0.05%)
QQQ   438.28 (+0.69%)
AAPL   181.05 (-0.20%)
MSFT   407.62 (-0.02%)
META   488.94 (+1.02%)
GOOGL   136.96 (+0.43%)
AMZN   174.60 (+0.83%)
TSLA   200.76 (-0.63%)
NVDA   792.88 (+2.09%)
NIO   5.66 (+4.24%)
AMD   187.02 (+5.94%)
BABA   74.17 (-0.56%)
T   17.00 (+0.24%)
F   12.43 (+1.06%)
MU   89.56 (-0.17%)
CGC   3.33 (-0.89%)
GE   155.99 (+0.24%)
DIS   111.46 (+0.60%)
AMC   4.38 (-12.22%)
PFE   26.97 (-0.26%)
PYPL   60.79 (+0.90%)
XOM   104.42 (+0.10%)
S&P 500   5,080.33 (+0.21%)
DOW   38,931.26 (-0.05%)
QQQ   438.28 (+0.69%)
AAPL   181.05 (-0.20%)
MSFT   407.62 (-0.02%)
META   488.94 (+1.02%)
GOOGL   136.96 (+0.43%)
AMZN   174.60 (+0.83%)
TSLA   200.76 (-0.63%)
NVDA   792.88 (+2.09%)
NIO   5.66 (+4.24%)
AMD   187.02 (+5.94%)
BABA   74.17 (-0.56%)
T   17.00 (+0.24%)
F   12.43 (+1.06%)
MU   89.56 (-0.17%)
CGC   3.33 (-0.89%)
GE   155.99 (+0.24%)
DIS   111.46 (+0.60%)
AMC   4.38 (-12.22%)
PFE   26.97 (-0.26%)
PYPL   60.79 (+0.90%)
XOM   104.42 (+0.10%)

Roquefort Therapeutics (ROQ) Competitors

GBX 8.13
-0.62 (-7.09%)
(As of 03:50 PM ET)

ROQ vs. SNG, BVX, BSFA, NSCI, ONC, SBTX, VAL, OCTP, IMM, and GENF

Should you be buying Roquefort Therapeutics stock or one of its competitors? The main competitors of Roquefort Therapeutics include Synairgen (SNG), BiVictriX Therapeutics (BVX), BSF Enterprise (BSFA), NetScientific (NSCI), Oncimmune (ONC), SkinBioTherapeutics (SBTX), ValiRx (VAL), Oxford Cannabinoid Technologies (OCTP), ImmuPharma (IMM), and Genflow Biosciences (GENF). These companies are all part of the "biotechnology" industry.

Roquefort Therapeutics vs.

Roquefort Therapeutics (LON:ROQ) and Synairgen (LON:SNG) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and community ranking.

Roquefort Therapeutics has higher earnings, but lower revenue than Synairgen.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Roquefort Therapeutics£637.0016,483.35-£1.64MN/AN/A
Synairgen£79K132.25-£42.87M-£0.05-103.76

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Roquefort Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Synairgen
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

1.7% of Roquefort Therapeutics shares are owned by institutional investors. Comparatively, 28.8% of Synairgen shares are owned by institutional investors. 51.5% of Roquefort Therapeutics shares are owned by company insiders. Comparatively, 3.3% of Synairgen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Roquefort Therapeutics has a beta of -0.08, indicating that its stock price is 108% less volatile than the S&P 500. Comparatively, Synairgen has a beta of -2.23, indicating that its stock price is 323% less volatile than the S&P 500.

In the previous week, Roquefort Therapeutics had 1 more articles in the media than Synairgen. MarketBeat recorded 1 mentions for Roquefort Therapeutics and 0 mentions for Synairgen. Synairgen's average media sentiment score of 0.67 beat Roquefort Therapeutics' score of 0.00 indicating that Synairgen is being referred to more favorably in the news media.

Company Overall Sentiment
Roquefort Therapeutics Neutral
Synairgen Positive

Synairgen received 153 more outperform votes than Roquefort Therapeutics when rated by MarketBeat users.

CompanyUnderperformOutperform
Roquefort TherapeuticsN/AN/A
SynairgenOutperform Votes
153
56.46%
Underperform Votes
118
43.54%

Roquefort Therapeutics' return on equity of -33.20% beat Synairgen's return on equity.

Company Net Margins Return on Equity Return on Assets
Roquefort TherapeuticsN/A -33.20% -19.04%
Synairgen N/A -48.86%-30.58%

Summary

Roquefort Therapeutics beats Synairgen on 7 of the 12 factors compared between the two stocks.


Get Roquefort Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ROQ and its competitors with MarketBeat's FREE daily newsletter.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ROQ vs. The Competition

MetricRoquefort TherapeuticsBiotechnology IndustryMedical SectorLON Exchange
Market Cap£10.50M£581.21M£4.97B£1.34B
Dividend YieldN/A3.47%2.87%12.11%
P/E Ratio-381.25247.41192.621,690.84
Price / Sales16,483.3525,077.653,024.89407,739.47
Price / Cash1.4911.4494.4832.63
Price / Book1.635.784.482.50
Net Income-£1.64M-£24.49M£112.73M£182.31M
7 Day Performance4.90%0.48%5.35%-0.19%
1 Month Performance20.44%3.93%10.50%-0.42%
1 Year Performance10.24%75.71%13.09%5.89%

Roquefort Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SNG
Synairgen
0 of 5 stars
GBX 5.03
-0.6%
N/A-52.5%£10.12M£79,000.00-100.5530Gap Down
BVX
BiVictriX Therapeutics
0 of 5 stars
GBX 11.50
flat
N/A-30.9%£9.49MN/A-287.5017
BSFA
BSF Enterprise
0 of 5 stars
GBX 8.75
flat
N/A-49.2%£9.04MN/A-437.5012
NSCI
NetScientific
0 of 5 stars
GBX 69.50
-0.7%
N/A-15.5%£16.65M£1.38M-534.6226
ONC
Oncimmune
0 of 5 stars
GBX 23.10
-1.7%
N/A-44.0%£17.13M£3.03M-165.0052Gap Down
High Trading Volume
SBTX
SkinBioTherapeutics
0 of 5 stars
GBX 9.10
-6.7%
N/A-58.2%£17.37M£21,949.00-455.0011
VAL
ValiRx
0 of 5 stars
GBX 4.25
-1.2%
N/A-63.0%£5.63MN/A-141.678News Coverage
Negative News
OCTP
Oxford Cannabinoid Technologies
0 of 5 stars
GBX 0.46
+3.9%
N/A-43.2%£4.98MN/A-53.107Gap Up
IMM
ImmuPharma
0 of 5 stars
GBX 1.11
flat
N/A-51.1%£4.60M£94,819.00-110.5013Gap Down
GENF
Genflow Biosciences
0 of 5 stars
GBX 1.55
+12.7%
N/A-38.9%£4.53MN/A-256.005Gap Down

Related Companies and Tools

This page (LON:ROQ) was last updated on 2/29/2024 by MarketBeat.com Staff